The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
PT-112 in advanced metastatic castrate-resistant prostate cancer (mCRPC), as monotherapy or in combination with PD-L1 inhibitor avelumab: Findings from two phase I studies.
 
Alan Haruo Bryce
Honoraria - Astellas Pharma
Travel, Accommodations, Expenses - Clovis Oncology
 
Roxana Stefania Dronca
Research Funding - Merck Sharp & Dohme (Inst)
Other Relationship - Elsevier
 
Brian Addis Costello
Research Funding - GlaxoSmithKline/Novartis (Inst)
 
Jeffrey R. Infante
Research Funding - Aileron Therapeutics (Inst); ARMO BioSciences (Inst); AstraZeneca (Inst); BioMed Valley Discoveries (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Calithera Biosciences (Inst); Celldex (Inst); Celldex (Inst); eFFECTOR Therapeutics (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Immunocore (Inst); Janssen Oncology (Inst); MedImmune (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Phosplatin Therapeutics (Inst); Roche (Inst); Roche (Inst); Tesaro (Inst)
 
Tyler David Ames
Employment - Phosplatin Therapeutics
Stock and Other Ownership Interests - Phosplatin Therapeutics
 
Jose Jimeno
Employment - Phosplatin Therapeutics
Leadership - Phosplatin Therapeutics
Stock and Other Ownership Interests - Phosplatin Therapeutics
 
Daniel D. Karp
Consulting or Advisory Role - Black Beret Life Sciences
Research Funding - Phosplatin Therapeutics
Travel, Accommodations, Expenses - Phosplatin Therapeutics